PET-CT is a system that consists of a combination of PET (Positron Emission Tomography) and CT (Computed Tomography) to evaluate functional level images with cross-sectional anatomical information. PET provides information about the function and metabolism of cells; CT provides anatomical data such as size, placement and density.

PET-CT is important in determining the prevalence of cancer patients, choosing the treatment to be applied, and examining suspicious cases such as recurrence. It plays an important role in determining the staging method (surgery, surgery + chemotherapy, radiotherapy, chemotherapy, radiotherapy). In addition, other diagnostic methods, such as bone, liver lesions, lymph nodes or lung nodules, such as whether the findings are related to the patient's current tumor makes it possible to perform a more accurate staging.

In oncology patients, the separation of benign masses, the staging of cancer, the prevalence of the tumor in the organ, the determination of the recurrence of the body, the determination of the recurrence, the selection of the treatment method, the evaluation of the treatment response, the determination of the actual tumor volume in the planning of the radiotherapy used. Supports all assessments with numeric information. In the oncological patient group, PET-CT is a method that displays the whole body at a time and provides more information than all other imaging methods.

Usage Areas

Nuclear medicine applications are mostly used in the oncological sense to scan the whole body. To determine the main focus in cancer-diagnosed patients, to determine the main focus in patients diagnosed with cancer, to determine the prevalence of the nodules or masses previously diagnosed in patients, to determine the prevalence of other body regions. In the evaluation of the response, recurrence (renewal) or suspicion of metastasis (spreading elsewhere), recently in the planning of radiotherapy and to be irradiated live cancer tissue more accurately determine and contribute to the protection of healthy tissues.

It is used in the differential diagnosis of solitary pulmonary nodules, brain tumors, pancreatic masses and adrenal gland masses.
In the evaluation of treatment response; In the event of a successful response, chemotherapy may be decided earlier to continue chemotherapy or, if necessary, to replace chemotherapy drugs (for example, if the cancerous tissue resists treatment).

It has an important role in the investigation of the presence of live muscle tissue before the intervention of the stent, such as by-pass and stent, in the selected heart patients and thus to determine whether these interventions are beneficial.

It is used in psychiatry and neurological sciences to show brain glucose metabolism, oxygen consumption and blood flow with different agents, to detect epilepsy foci, and to monitor many nervous system related receptors and molecules. It can now be used to evaluate the status of dopamine receptors in Parkinson's patients and to monitor response to treatment. It can also be applied in the differential diagnosis of other movement disorders.

What are the preliminary preparations for PET-CT patients?

For PET-CT, patients should be hungry for 6 hours before the examination. Patients may take oral antidiabetic or non-insulin drugs. In diabetic patients, image quality may be poor because of the competition of blood glucose with FDG. For this reason, blood glucose level is determined before FDG injection and it is generally not recommended to perform blood glucose levels above 180 mg / dL.

How is PET-CT imaging performed?

During PET-CT imaging, the resting patient is injected intravenously with a special radiopharmaceutical called FDG (Fluorodeoxyglucose). After waiting for approximately 60 minutes for FDG to accumulate in cancerous tissues, an approximate 20-25 min. If necessary, a second imaging can be performed after 2 hours.

Ask Liv Expert